Journal of Thoracic Oncology最新文献

筛选
英文 中文
OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC) OA13.04 ALINA安全性结果:ALK+非小细胞肺癌 (NSCLC) 患者辅助治疗 Alectinib 与化疗的比较
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.070
{"title":"OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC)","authors":"","doi":"10.1016/j.jtho.2024.09.070","DOIUrl":"10.1016/j.jtho.2024.09.070","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA09.03 Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) OA09.03 SAF-189s 与克唑替尼(Crizotinib)治疗一线 ALK 阳性晚期非小细胞肺癌 (NSCLC) 的随机、开放标签 III 期研究
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.053
{"title":"OA09.03 Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","authors":"","doi":"10.1016/j.jtho.2024.09.053","DOIUrl":"10.1016/j.jtho.2024.09.053","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MA01.13 Adherence to Treatment Protocol of Patients Submitted to Neoadjuvant (Chemo) Immunotherapy in Resectable NSCLC: Ameta Analysis MA01.13 接受新辅助(化疗)免疫疗法的可切除 NSCLC 患者对治疗方案的依从性:艾美塔分析
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.099
{"title":"MA01.13 Adherence to Treatment Protocol of Patients Submitted to Neoadjuvant (Chemo) Immunotherapy in Resectable NSCLC: Ameta Analysis","authors":"","doi":"10.1016/j.jtho.2024.09.099","DOIUrl":"10.1016/j.jtho.2024.09.099","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142440934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Title Page 标题页
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/S1556-0864(24)02285-8
{"title":"Title Page","authors":"","doi":"10.1016/S1556-0864(24)02285-8","DOIUrl":"10.1016/S1556-0864(24)02285-8","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142440975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA15.03 Clinicogenomic Landscape of Lymph Node Metastases in TRACERx OA15.03 TRACERx 淋巴结转移的临床基因组学特征
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.076
{"title":"OA15.03 Clinicogenomic Landscape of Lymph Node Metastases in TRACERx","authors":"","doi":"10.1016/j.jtho.2024.09.076","DOIUrl":"10.1016/j.jtho.2024.09.076","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142441146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA01.05 Neoadjuvant Nivolumab with or without Relatlimab in Resectable NSCLC: Additional Analysis and Extended Follow-up OA01.05 新辅助 Nivolumab 联合或不联合 Relatlimab 治疗可切除的 NSCLC:补充分析和延长随访
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.024
{"title":"OA01.05 Neoadjuvant Nivolumab with or without Relatlimab in Resectable NSCLC: Additional Analysis and Extended Follow-up","authors":"","doi":"10.1016/j.jtho.2024.09.024","DOIUrl":"10.1016/j.jtho.2024.09.024","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142441472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MA02.07 AI as Primary Reader in 4-IN-THE-LUNG-RUN Lung Cancer Screening Trial: Impact on Negative Misclassification and Referral Rate MA02.07 AI作为4-IN-THE-LUNG-RUN肺癌筛查试验的主要读者:对阴性错误分类和转诊率的影响
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.103
{"title":"MA02.07 AI as Primary Reader in 4-IN-THE-LUNG-RUN Lung Cancer Screening Trial: Impact on Negative Misclassification and Referral Rate","authors":"","doi":"10.1016/j.jtho.2024.09.103","DOIUrl":"10.1016/j.jtho.2024.09.103","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA16.05 Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1 OA16.05 曲妥珠单抗地罗替康单药治疗预处理HER2-表达的非鳞状非小细胞肺癌:DESTINY-Lung03 第一部分
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.082
{"title":"OA16.05 Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1","authors":"","doi":"10.1016/j.jtho.2024.09.082","DOIUrl":"10.1016/j.jtho.2024.09.082","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA12.04 Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery for Stage III-N2 NSCLC: SQUAT Trial (WJOG 12119L) OA12.04 III-N2 期 NSCLC 手术后的新辅助化疗-免疫-放疗并行疗法:SQUAT 试验(WJOG 12119L)
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.066
{"title":"OA12.04 Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery for Stage III-N2 NSCLC: SQUAT Trial (WJOG 12119L)","authors":"","doi":"10.1016/j.jtho.2024.09.066","DOIUrl":"10.1016/j.jtho.2024.09.066","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PL02.04 Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: Primary Analysis of HARMONi-2 PL02.04 Ivonescimab (AK112) 与 Pembrolizumab 作为 PD-L1 阳性晚期 NSCLC 一线治疗的 3 期研究:HARMONi-2 的初步分析
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2024-10-01 DOI: 10.1016/j.jtho.2024.09.012
{"title":"PL02.04 Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: Primary Analysis of HARMONi-2","authors":"","doi":"10.1016/j.jtho.2024.09.012","DOIUrl":"10.1016/j.jtho.2024.09.012","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142440976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信